SG10201912216VA - Benzenesulfonamide compounds and their use as therapeutic agents - Google Patents
Benzenesulfonamide compounds and their use as therapeutic agentsInfo
- Publication number
- SG10201912216VA SG10201912216VA SG10201912216VA SG10201912216VA SG10201912216VA SG 10201912216V A SG10201912216V A SG 10201912216VA SG 10201912216V A SG10201912216V A SG 10201912216VA SG 10201912216V A SG10201912216V A SG 10201912216VA SG 10201912216V A SG10201912216V A SG 10201912216VA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic agents
- benzenesulfonamide compounds
- benzenesulfonamide
- compounds
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662339773P | 2016-05-20 | 2016-05-20 | |
US201662432152P | 2016-12-09 | 2016-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201912216VA true SG10201912216VA (en) | 2020-02-27 |
Family
ID=58794232
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809702SA SG11201809702SA (en) | 2016-05-20 | 2017-05-19 | Benzenesulfonamide compounds and their use as therapeutic agents |
SG10201912216VA SG10201912216VA (en) | 2016-05-20 | 2017-05-19 | Benzenesulfonamide compounds and their use as therapeutic agents |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809702SA SG11201809702SA (en) | 2016-05-20 | 2017-05-19 | Benzenesulfonamide compounds and their use as therapeutic agents |
Country Status (17)
Country | Link |
---|---|
US (4) | US10246453B2 (en) |
EP (1) | EP3458449A1 (en) |
JP (3) | JP6938545B2 (en) |
KR (1) | KR102366077B1 (en) |
CN (1) | CN109526219B (en) |
AU (2) | AU2017268006B2 (en) |
CA (1) | CA3023465A1 (en) |
CL (1) | CL2018003260A1 (en) |
CO (1) | CO2018012485A2 (en) |
IL (1) | IL262834B (en) |
MX (1) | MX2018013985A (en) |
PH (1) | PH12018502378A1 (en) |
RU (1) | RU2769827C2 (en) |
SG (2) | SG11201809702SA (en) |
TN (1) | TN2018000385A1 (en) |
WO (1) | WO2017201468A1 (en) |
ZA (1) | ZA201807518B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3023465A1 (en) | 2016-05-20 | 2017-11-23 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
EP3551626B1 (en) | 2016-12-09 | 2023-10-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
AU2019285184B2 (en) * | 2018-06-13 | 2023-11-16 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
BR112021000209A2 (en) | 2018-08-31 | 2021-08-24 | Xenon Pharmaceuticals Inc. | Heteroaryl Substituted Sulphonamide Compounds and Their Use as Therapeutic Agents |
US10752623B2 (en) | 2018-08-31 | 2020-08-25 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
US20230404913A1 (en) * | 2020-10-13 | 2023-12-21 | Xenon Pharmaceuticals, Inc. | Pharmaceutical formulations for treating diseases associated with voltage-gated sodium channels |
TW202220647A (en) * | 2020-10-13 | 2022-06-01 | 加拿大商再諾製藥公司 | Pharmaceutical formulations for treating diseases associated with voltage-gated sodium channels |
WO2023235734A1 (en) | 2022-06-02 | 2023-12-07 | Neurocrine Biosciences, Inc. | Deuterated compounds |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
PT981327E (en) | 1997-05-07 | 2003-02-28 | Galen Chemicals Ltd | INTRAVAGINAL DETERMINATIONS OF LIBERATION OF DRUGS FOR THE ADMINISTRATION OF TESTOSTERONE AND TESTEROSTERONE PERCURSORS |
AU2201500A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
ATE250932T1 (en) | 1999-07-16 | 2003-10-15 | Warner Lambert Co | METHOD FOR TREATING CHRONIC PAIN BY ADMINISTRATION OF A MEK INHIBITOR |
GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
FR2836917B1 (en) | 2002-03-11 | 2006-02-24 | Lipha | NITROSO DIPHENYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS MEDICAMENTS FOR THE TREATMENT OF DISEASES CHARACTERIZED BY OXIDATIVE STRESS SITUATION |
EP2471533A1 (en) | 2002-06-27 | 2012-07-04 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
WO2004092123A2 (en) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
EP1646628A1 (en) | 2003-07-08 | 2006-04-19 | Novartis AG | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
JP2007501804A (en) | 2003-08-08 | 2007-02-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compositions useful as inhibitors of voltage-gated sodium channels |
HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
WO2006038594A1 (en) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N-type calcium channel inhibitor |
JP2008524244A (en) | 2004-12-17 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | Hydroxyl steroid dehydrogenase inhibitor |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
CA2624726A1 (en) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
JP2009524591A (en) * | 2005-12-21 | 2009-07-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | Heterocyclic derivatives as modulators of ion channels |
CN101506165B (en) | 2006-08-15 | 2012-07-04 | 霍夫曼-拉罗奇有限公司 | Phenyl, pyridine and quinoline derivatives |
ZA200902384B (en) | 2006-10-19 | 2010-07-28 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
CA2694748A1 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
EP2173743A2 (en) | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
WO2009013171A2 (en) | 2007-07-24 | 2009-01-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
EP2289868B1 (en) | 2008-06-25 | 2014-08-13 | Daiichi Sankyo Company, Limited | Carboxylic acid compound |
MX2010014193A (en) | 2008-07-01 | 2011-02-22 | Vertex Pharma | Heterocyclic derivatives as modulators of ion channels. |
US20110294853A1 (en) | 2008-09-12 | 2011-12-01 | Benjamin Pelcman | Bis Aromatic Compounds for Use in the Treatment of Inflammation |
NZ593473A (en) | 2009-01-12 | 2013-02-22 | Pfizer Ltd | Sulfonamide derivatives |
WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
MX2013001970A (en) | 2010-08-20 | 2013-08-09 | Hutchison Medipharma Ltd | Pyrrolopyrimidine compounds and uses thereof. |
JP2014521749A (en) | 2011-08-17 | 2014-08-28 | アムジエン・インコーポレーテツド | Heteroaryl sodium channel inhibitor |
KR20140095067A (en) | 2011-10-28 | 2014-07-31 | 머크 샤프 앤드 돔 코포레이션 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
CN104093716B (en) * | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | Biaryl ether sulfonamide compounds and its purposes as therapeutic agent |
ES2586213T3 (en) * | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
MX2014014234A (en) * | 2012-05-22 | 2015-05-07 | Genentech Inc | N-substituted benzamides and their use in the treatment of pain. |
JP6251275B2 (en) | 2012-10-15 | 2017-12-20 | デウン ファーマシューティカル カンパニー リミテッド | Sodium channel inhibitor, its production method and its use |
JP2015535252A (en) | 2012-10-26 | 2015-12-10 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | N-substituted indazolesulfonamide compounds having selective activity in voltage-gated sodium channels |
US9624208B2 (en) | 2012-10-26 | 2017-04-18 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
TW201443025A (en) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | Chemical compounds |
TW201512171A (en) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | Chemical compounds |
US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
EP3044219A1 (en) | 2013-09-09 | 2016-07-20 | Bristol-Myers Squibb Company | Rorgamma modulators |
CA2922851C (en) | 2013-09-10 | 2023-03-14 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
KR20160090846A (en) * | 2013-11-27 | 2016-08-01 | 제넨테크, 인크. | Substituted benzamides and methods of use thereof |
WO2015077905A1 (en) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
WO2015099841A1 (en) | 2013-12-23 | 2015-07-02 | Purdue Pharma L.P. | Indazoles and use thereof |
WO2016007534A1 (en) * | 2014-07-07 | 2016-01-14 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
WO2016177340A1 (en) | 2015-05-05 | 2016-11-10 | 上海海雁医药科技有限公司 | Bicyclic substituted benzene sulfonamide derivative, and preparation method and pharmaceutical use thereof |
AU2016370677A1 (en) | 2015-12-18 | 2018-06-07 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
CA3023465A1 (en) | 2016-05-20 | 2017-11-23 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
EP3541373B1 (en) | 2016-11-17 | 2023-11-01 | Merck Sharp & Dohme LLC | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
EP3551626B1 (en) | 2016-12-09 | 2023-10-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
AU2019285184B2 (en) * | 2018-06-13 | 2023-11-16 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
US10752623B2 (en) | 2018-08-31 | 2020-08-25 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
-
2017
- 2017-05-19 CA CA3023465A patent/CA3023465A1/en active Pending
- 2017-05-19 US US15/600,490 patent/US10246453B2/en active Active
- 2017-05-19 JP JP2018560884A patent/JP6938545B2/en active Active
- 2017-05-19 RU RU2018145045A patent/RU2769827C2/en active
- 2017-05-19 AU AU2017268006A patent/AU2017268006B2/en active Active
- 2017-05-19 EP EP17726487.6A patent/EP3458449A1/en active Pending
- 2017-05-19 KR KR1020187036489A patent/KR102366077B1/en active IP Right Grant
- 2017-05-19 TN TNP/2018/000385A patent/TN2018000385A1/en unknown
- 2017-05-19 SG SG11201809702SA patent/SG11201809702SA/en unknown
- 2017-05-19 SG SG10201912216VA patent/SG10201912216VA/en unknown
- 2017-05-19 WO PCT/US2017/033634 patent/WO2017201468A1/en unknown
- 2017-05-19 CN CN201780042625.6A patent/CN109526219B/en active Active
- 2017-05-19 MX MX2018013985A patent/MX2018013985A/en unknown
-
2018
- 2018-11-06 IL IL262834A patent/IL262834B/en unknown
- 2018-11-08 ZA ZA2018/07518A patent/ZA201807518B/en unknown
- 2018-11-12 PH PH12018502378A patent/PH12018502378A1/en unknown
- 2018-11-16 CL CL2018003260A patent/CL2018003260A1/en unknown
- 2018-11-21 CO CONC2018/0012485A patent/CO2018012485A2/en unknown
-
2019
- 2019-02-28 US US16/289,212 patent/US10662184B2/en active Active
-
2020
- 2020-03-17 US US16/821,294 patent/US10815229B1/en active Active
- 2020-07-28 US US16/940,696 patent/US11299490B2/en active Active
-
2021
- 2021-06-08 AU AU2021203771A patent/AU2021203771B2/en active Active
- 2021-09-01 JP JP2021142186A patent/JP2021185189A/en not_active Withdrawn
-
2023
- 2023-06-16 JP JP2023099277A patent/JP2023108032A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256383A1 (en) | Therapeutic agents | |
GB201709456D0 (en) | Therapeutic agents | |
HK1247614A1 (en) | Therapeutic compounds and uses thereof | |
IL267143A (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
ZA201807518B (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
GB201509893D0 (en) | Therapeutic agents | |
GB201517263D0 (en) | Therapeutic agents | |
GB201603104D0 (en) | Therapeutic agents | |
IL250990A0 (en) | Human therapeutic agents | |
HK1248697A1 (en) | Therapeutic compounds and uses thereof | |
GB201617064D0 (en) | Compounds and their therapeutic use | |
ZA201802256B (en) | Compounds and therapeutic uses thereof | |
GB201715194D0 (en) | Compounds and their therapeutic use | |
IL278949A (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
GB201608797D0 (en) | Therapeutic use | |
GB201509885D0 (en) | Therapeutic agents | |
GB201509888D0 (en) | Therapeutic agents | |
IL265269B (en) | Novel compounds and therapeutic uses thereof | |
GB201418809D0 (en) | Therapeutic agents and uses thereof | |
GB201700553D0 (en) | Therapeutic agents | |
EP3302530A4 (en) | Cdh26 based therapeutic agents and their use | |
GB201513299D0 (en) | Therapeutic agents | |
GB201700526D0 (en) | Therapeutic use | |
GB201600376D0 (en) | Novel therapeutic agents | |
GB201521767D0 (en) | Therapeutic agents |